Weekly Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings as of May 17, 2018

May 17, 2018 - By Julia Grubbs

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Corporate Logo
Big Money Sentiment decreased to 1.21 in 2017 Q4. It has change of 1.12, from 2017Q3’s 2.33. The ratio worsened due to Amicus Therapeutics, Inc. positioning: 25 sold and 48 reduced. 25 funds acquired positions and 63 increased positions. Investors holded 192.70 million in 2017Q3 but now own 197.59 million shares or 2.54% more.
Guggenheim Cap Ltd Com holds 0.01% or 209,883 shs. Acuta Capital Prns Limited Liability, a California-based fund reported 43,900 shs. Prelude Capital Management Llc owns 48,848 shs. 66,000 are owned by Neuberger Berman Group Ltd Co. Ameritas Prtn, Nebraska-based fund reported 14,057 shs. 32,006 were reported by Barclays Public Ltd Co. Omega Advsrs has 100,000 shs for 0.05% of their capital. Susquehanna International Ltd Liability Partnership stated it has 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Fortaleza Asset stated it has 7,215 shs. Alliancebernstein Limited Partnership owns 256,846 shs for 0% of their capital. Thompson Davis & Inc owns 2,827 shs for 0.1% of their capital. Legal & General Public Limited Com accumulated 0% or 69,951 shs. State Street holds 0.01% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 7.84 million shs. Proshare Advisors Lc holds 114,365 shs or 0.01% of its capital. Palo Alto Limited Liability Company holds 3.72% or 6.01 million shs in its capital.

Amicus Therapeutics, Inc. registered $3.87 million net activity with 3 insider buys and 18 sales since December 11, 2017. On Tuesday, January 2 Baird William D III also sold $147,181 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD). Shares for $73,559 were sold by Barth Jay on Tuesday, January 2. The insider Quimi Daphne sold 8,750 shs worth $131,250. The insider Andrews Kurt J. sold 5,000 shs worth $71,343. HAYDEN DONALD J JR sold $300,002 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, January 2. The insider Crowley John F sold $164,973.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

In total 2 analysts cover Amicus Therapeutics (NASDAQ:FOLD). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:FOLD)’s analyst reports since February 8, 2018 according to StockzIntelligence Inc. On Thursday, February 8 the firm earned “Outperform” rating by Leerink Swann. On Wednesday, February 7 the firm has “Buy” rating by Robert W. Baird given. Listed here are Amicus Therapeutics, Inc. (NASDAQ:FOLD) PTs and latest ratings.

07/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $20.0 Maintain
08/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $20 New Target: $24 Maintain

The stock increased 9.18% or $1.35 during the last trading session, reaching $16.06.Amicus Therapeutics, Inc. has 3.20 million shares volume, 19.83% up from normal. FOLD is uptrending and has moved 90.40% since May 17, 2017. FOLD outperformed the S&P500 by 78.85%.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.The firm is worth $3.03 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies.Last it reported negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.